EHS
EHS

STAT Plus: Pharmalittle: AstraZeneca to freeze U.S. price hikes; Merck to market Keytruda in China at what price?

Hello, everyone, and how are you this morning? We are doing just fine, thank you, now that the short person has left for the summer job and our official mascots have quietly settled into their official snoozing positions. As for us, no snoozing is allowed. There is much to be done. So please join us as we fire up the coffee kettle for another cup of stimulation — southern pecan is the choice of the day, for those who track such things. Meanwhile, here are some items of interest to help you on your journey. Hope all goes well and, as always, please do keep in touch …

AstraZeneca (AZN) is the latest drug maker to freeze prices in the U.S. for the rest of 2018, Reuters writes. The move comes as the Trump administration tries to complete a blueprint for lowering drug costs and, in particular, follows criticism from President Trump as he struggles to follow through on an oft-stated commitment to solve the problem. In recent weeks, Pfizer (PFE), Novartis (NVS) and Roche (RHHBY) agreed to either defer or freeze price cuts through the rest of the year.

Continue to STAT Plus to read the full story…

Source link

EHS
Back to top button